July/August 2022 • PharmaTimes Magazine • 34-35
// YOUR MOVES //
Your Moves
Mover of the Month
Tobias Hauser has joined Limbic as its Head of Computational Psychiatry.
Tobias has worked at the intersection of psychiatry, neuroscience and artificial intelligence and is one of the leaders in the field of cognitive neuroscience and computational psychiatry.
He joins the company with a PhD in Child and Adolescent Psychiatry and experience heading up Development Computational Psychiatry at University College London, where he led the Developmental Computational Psychiatry group from 2018.
At Limbic, Hauser will be working on a variety of projects in the realm of machine learning and mental health. Hauser will be bringing his cutting-edge research expertise in the space to a real-world setting, with a focus on building solutions that see patients assessed with more scientific rigour, which in turn leads to longer lasting results.
BioAgilytix Labs has announced the appointment of Euan Menzies as Chairman and CEO. Meanwhile, Jim Datin is retiring from his executive management role but will continue to serve as a non-executive member of the Board of Directors.
Euan joins BioAgilytix with significant experience and a proven background as CEO and Chairman of several software and business services companies. Most notably, he was CEO at Bioclinica until its successful merger with ERT (now Clario) in April 2021.
Previous roles include over ten years as CEO at Vertafore – a successful financial services software company. Prior to that he was a senior executive with The Thomson Corporation.
I Holland – the manufacturer of tablet tooling for the pharmaceutical and nutraceutical markets – has announced the appointment of Borja Guerra as the company’s new Director, Sales and Marketing.
Borja joins I Holland with more than 20 years’ experience in a variety of sales and marketing leadership roles within pharma, having most recently served as a Director at Kilian, a global manufacturer of packing and process technology.
In his new role, Borja will oversee and direct all aspects of I Holland’s sales and marketing activities and will be responsible for expanding the company’s global business and building key relationships with customers in the marketplace.
Alzheimer’s Research UK has announced that Biotech clinical development leader and former UK Vaccines Taskforce member Divya Chadha Manek OBE and former BBC executive Amanda Farnsworth have joined its Board of Trustees.
In their voluntary roles they will provide strategic leadership, governance and insight into the charity’s running, and they will meet with the rest of the 12-strong Board five times a year.
They both bring a wealth of skills and experience to the UK’s leading dementia research charity as it goes through a crucial phase in its 30-year history. The need for investment in dementia research has never been more urgent and the charity is currently overcoming huge challenges caused by the COVID-19 pandemic to continue to make breakthroughs possible.
Brevia Health has appointed Professor Gillian Leng CBE to its Advisory Board. Gillian brings a wealth of experience from her background in healthcare and the life sciences sector.
She was on the Board of the National Institute for Health and Care Excellence (NICE) for over 20 years and was most recently its Chief Executive.
Gillian has close knowledge of the health and care system, both as a frontline clinician and through her work to improve patient access to effective new treatments and interventions. Furthermore, she has worked closely with government on new policy developments, including the Office for Life Sciences.
She also has extensive media experience, including appearances on the Today programme, BBC Breakfast, Radio 5 Live and Radio 4’s Woman’s Hour.
DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, has expanded its Commercial team, appointing Supriya Mathur to the newly created role of Global Head of Communications.
Supriya brings over 20 years of strategic communications experience, advising both private and public companies, especially in life sciences, through their development cycle. Having worked previously with Capital MSL and, most recently, as Director at Optimum Strategic Communications, she has extensive international experience, working with companies throughout Europe, the US and Asia.
Peter Kelly – Managing Director at Accord UK – has been elected as Chair of the British Generic Manufacturers Association (BGMA).
Peter, who was previously Vice-chair, replaces Peter Ballard, will take on the role for two years and has 20 years’ experience in the pharmaceutical industry, the last 15 years being at Accord in a number of senior commercial roles.
His appointment is one of many Accord-elected roles at the BGMA in recent months. Joe Leddy, Senior Director EHS EMENA, was invited to chair the BGMA Sustainability Working Group, and Matthew Daly has been Vice-chair of the Secondary Care Working Group since 2020.
DFE Pharma has appointed Marie-Louise Mans as Global Human Resources Director and a member of the wider leadership team. DFE Pharma, headquartered in Goch, Germany, has facilities in nine different countries, employing around 450 people globally.
A senior human resource professional with decades of experience with global corporates, Marie-Louise joins from Royal Reesink, a global distributor and services provider employing over 3,000 people, where she worked as Group HR Director.
The appointment reflects DFE Pharma’s ambition to expand in several areas across the pharma and biopharma sectors.
CN Bio has revealed that Dr Paul Brooks is its new Chief Business Officer. Paul will be responsible for shaping the company’s commercial business strategy and lead the expansion of its global commercial organisation.
He joins CN Bio backed by over 20 years of key industry experience, having previously provided strategic transformative approaches in his role as Head of Business Operations & Managing Director at Horizon Discovery. Prior to that, Paul held various managerial roles at Sigma-Aldrich.
Evonetix, the synthetic biology company, has announced the appointment of Colin McCracken as Chief Executive Officer. Colin’s appointment will support the next phase of the company’s development and the commercialisation of its semiconductor-based DNA synthesis platform.
Colin brings over 20 years’ experience in commercial and business development roles. Prior to joining Evonetix he was Senior Vice President and Chief Commercial Officer at Fluidigm Corp, where he was responsible for leading all commercial activities, driving revenue growth, and expanding the Company’s global reach.
He has delivered commercial success in numerous other leadership positions, including Vice President and General Manager and Vice President of Sales at Thermo Fisher Scientific, Vice President and Head of European Sales at Life Technologies and National Sales Manager at Qiagen.
Element has appointed Dr Michael Kipping as Director of Medical Technologies for Europe and Nicole Small as Senior Manager of the Medical Technology team.
Prior to joining Element, Michael was Health Innovation Lead at Innovate UK (UKRI); responsible for running the primary grant funding programme that supports innovative UK health and life sciences businesses.
Meanwhile, Nicole was previously a senior manager at the Medicines and Healthcare Products Regulatory Agency Devices Safety and Surveillance division. She has led major change, educational and operational programmes to ensure the safety of devices driven by benefit-risk assessments.
In his position at Element, Michael will drive the growth of the medical business across Europe and Nicole will be forming a new team focused on enabling medical technology manufacturers to navigate the complex field of market access and the testing requirements necessary for safety and performance.
Astellas has appointed Phil Tennant as Senior Vice President and Head of the Oncology Business Unit, replacing Steve Sabus. In this new role, Phil will be responsible for all commercial activities to support marketed products, Astellas’ co-promotion partners and commercial planning for early-stage oncology development compounds.
Most recently, Phil was Senior Vice President and Head of the Oncology Strategic Brand Marketing organisation, overseeing the global teams supporting priority oncology brands, including marketed and pre-launch products.
Owen Mumford, which designs and manufactures medical devices today, has appointed Bal Johal as Director of Research and Development.
Bal brings a wealth of experience in the pharmaceutical and medical device sector, covering a range of therapeutic areas, most recently working as Vice President of product development at Circassia. Prior to this, she held roles within research and development at GlaxoSmithKline, Pfizer and Mundipharma Research Ltd.
PharmaTimes
PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.